Welcome to our dedicated page for KAIROS PHARMA SEC filings (Ticker: KAPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Kairos Pharma’s drug-development journey means parsing hundreds of pages filled with complex clinical data and ever-shifting risk factors. If you have struggled to locate a single Phase 2 trial update or to reconcile cash-runway figures buried deep in footnotes, you already know why Kairos Pharma SEC filings explained simply is more than a convenience—it is essential.
Stock Titan’s platform turns dense biotechnology disclosures into clear, actionable briefs. Our AI highlights which sections of the Kairos Pharma annual report 10-K simplified reveal R&D spend, safety signals, and biomarker strategy, and pinpoints fresh liquidity data inside each Kairos Pharma quarterly earnings report 10-Q filing. You will also receive real-time alerts for every Kairos Pharma Form 4 insider transactions real-time submission, letting you monitor executive stock moves as they happen. Need context on sudden press releases? The service links each Kairos Pharma 8-K material events explained notice to its impact on trial timelines.
Whether you are modeling cash burn, comparing immuno-oncology pipelines, or watching Kairos Pharma insider trading Form 4 transactions, our coverage spans all filings: 10-K, 10-Q, 8-K, S-1, and proxy statements. Practical use cases include:
- Flagging safety updates before earnings calls with Kairos Pharma earnings report filing analysis
- Reviewing Kairos Pharma proxy statement executive compensation to assess management incentives
- Understanding Kairos Pharma SEC documents with AI to gauge FDA-related risks
In short, our AI does the heavy lifting so you can focus on what matters—pipeline milestones and investment decisions—without sifting through technical jargon.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 884,938 shares of Kairos Pharma, Ltd. common stock, representing 4.99% of the class. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises shared voting and dispositive power over the securities under an Investment Management Agreement. Neither Armistice Capital nor Mr. Boyd claim sole voting or sole dispositive power; both report 0 sole and 884,938 shared voting and dispositive powers. The filing states the shares are held in the ordinary course of business and not acquired to influence control. The Schedule 13G/A is jointly filed and signed by Steven Boyd as Managing Member.
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing immunotherapy and cell therapy candidates. As of June 30, 2025, the company held $3,034 in cash and cash equivalents and reported a six-month net loss of $2,684. Operating expenses for the six months were $2,722, driven by $989 of R&D (including Phase 2 ENV105 prostate and Phase 1 ENV105 lung trials and a Phase 1 for KROS201) and $1,733 of general and administrative costs. Accumulated deficit was $11,499 and shareholders' equity was $5,997.
The company raised capital in 2025 via a January PIPE (net proceeds $3,058) and draws under a $30,000 Equity Line of Credit (ELOC), selling 3,510,000 ELOC shares for aggregate net proceeds of $3,903 as of the filing and an additional 3,000,000 ELOC shares for $3,693 in July 2025. Deferred offering costs totaled $1,692. Vendor advances, net, were $1,717 with significant amortization in the period. The company states current cash is expected to fund operations for at least 12 months, but continues to depend on future financings to execute its development plan.
FAQ
What is the current stock price of KAIROS PHARMA (KAPA)?
What is the market cap of KAIROS PHARMA (KAPA)?
